$372 Million is the total value of CHI Advisors LLC's 25 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Sell | PROMETHEUS BIOSCIENCES INC | $94,521,000 | +100.3% | 1,601,785 | -4.2% | 25.42% | +41.0% |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $71,230,000 | +186.2% | 3,409,758 | +9.8% | 19.15% | +101.5% |
| CGEM | Buy | CULLINAN ONCOLOGY INC | $41,578,000 | +6.4% | 3,243,185 | +6.4% | 11.18% | -25.1% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $37,237,000 | +0.6% | 3,069,847 | +16.0% | 10.01% | -29.2% |
| VECT | Buy | VECTIVBIO HLDG AG | $24,717,000 | +21.0% | 4,119,572 | +8.9% | 6.65% | -14.8% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $15,178,000 | -0.3% | 1,762,793 | -4.2% | 4.08% | -29.8% |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $10,928,000 | +267.9% | 3,415,148 | +125.4% | 2.94% | +159.1% |
| AKUS | Buy | AKOUOS INC | $8,709,000 | +122.1% | 1,288,358 | +54.1% | 2.34% | +56.3% |
| Sell | 2SEVENTY BIO INC | $7,715,000 | -28.7% | 530,223 | -35.3% | 2.07% | -49.8% | |
| KROS | Buy | KEROS THERAPEUTICS INC | $7,533,000 | +163.6% | 200,229 | +93.6% | 2.03% | +85.5% |
| CMPX | COMPASS THERAPEUTICS INC | $6,452,000 | -14.0% | 2,829,712 | 0.0% | 1.74% | -39.4% | |
| OMEGA THERAPEUTICS INC | $5,723,000 | +42.6% | 1,055,882 | 0.0% | 1.54% | +0.5% | ||
| INZY | Sell | INOZYME PHARMA INC | $5,350,000 | -44.9% | 1,996,277 | -1.8% | 1.44% | -61.2% |
| DTIL | Buy | PRECISION BIOSCIENCES INC | $4,777,000 | -0.6% | 3,674,820 | +22.3% | 1.28% | -30.1% |
| IKNA | Buy | IKENA ONCOLOGY INC | $4,311,000 | -10.8% | 1,214,304 | +11.3% | 1.16% | -37.2% |
| GTHX | Sell | G1 THERAPEUTICS INC | $4,046,000 | +6.8% | 323,945 | -57.8% | 1.09% | -24.8% |
| ORTX | Buy | ORCHARD THERAPEUTICS PLCspon ads | $3,994,000 | +28.8% | 7,987,396 | +50.5% | 1.07% | -9.3% |
| EIGR | Buy | EIGER BIOPHARMACEUTICALS INC | $3,427,000 | +186.3% | 455,100 | +139.5% | 0.92% | +101.5% |
| FRLN | Sell | FREELINE THERAPEUTICS HLDGSsponsored ads | $3,370,000 | -20.3% | 4,814,419 | -1.0% | 0.91% | -43.9% |
| New | RALLYBIO CORP | $2,811,000 | – | 194,297 | +100.0% | 0.76% | – | |
| ONCR | ONCORUS INC | $2,012,000 | -32.6% | 2,367,436 | 0.0% | 0.54% | -52.5% | |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $1,952,000 | -10.9% | 2,384,402 | +7.7% | 0.52% | -37.3% |
| OVID | OVID THERAPEUTICS INC | $1,591,000 | -14.4% | 864,822 | 0.0% | 0.43% | -39.7% | |
| NKTX | Sell | NKARTA INC | $1,548,000 | -64.9% | 117,599 | -67.2% | 0.42% | -75.3% |
| LABD | New | DIREXION SHS ETF TRdaily s&p biotec | $1,197,000 | – | 50,000 | +100.0% | 0.32% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INCcall | $0 | – | -100,000 | -100.0% | -0.00% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INCcall | $0 | – | -25,100 | -100.0% | -0.00% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -157,000 | -100.0% | -0.14% | – |
| PHAS | Exit | PHASEBIO PHARMACEUTICALS INC | $0 | – | -750,000 | -100.0% | -0.17% | – |
| Exit | ENTRADA THERAPEUTICS INC | $0 | – | -163,496 | -100.0% | -0.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.